BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12616340)

  • 1. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
    Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potencies of antagonists chemically related to iodoproxyfan at histamine H3 receptors in mouse brain cortex and guinea-pig ileum: evidence for H3 receptor heterogeneity?
    Schlicker E; Kathmann M; Bitschnau H; Marr I; Reidemeister S; Stark H; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):482-8. PubMed ID: 8740140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.
    Nickel T; Bauer U; Schlicker E; Kathmann M; Göthert M; Sasse A; Stark H; Schunack W
    Br J Pharmacol; 2001 Apr; 132(8):1665-72. PubMed ID: 11309237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
    Sadek B; Elz S; Pertz HH; Stark H; Schunack W
    Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel histamine H3 receptor antagonists: affinities in an H3 receptor binding assay and potencies in two functional H3 receptor models.
    Schlicker E; Kathmann M; Reidemeister S; Stark H; Schunack W
    Br J Pharmacol; 1994 Aug; 112(4):1043-8. PubMed ID: 7952862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.
    Krueger KM; Witte DG; Ireland-Denny L; Miller TR; Baranowski JL; Buckner S; Milicic I; Esbenshade TA; Hancock AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):271-81. PubMed ID: 15821027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of potency, affinity and selectivity of H3-antagonists: from thioperamide to thioperamide unrelated imidazole derivatives.
    Barocelli E; Ballabeni V; Caretta A; Bertoni S; Bordi F; Rivara S; Silva C; Mor M; Impicciatore M
    Farmaco; 1997; 52(6-7):463-9. PubMed ID: 9372599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H2 receptor-mediated facilitation and H3 receptor-mediated inhibition of noradrenaline release in the guinea-pig brain.
    Timm J; Marr I; Werthwein S; Elz S; Schunack W; Schlicker E
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Mar; 357(3):232-9. PubMed ID: 9550293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3-receptor antagonists: synthesis and structure-activity relationships of para- and meta-substituted 4(5)-phenyl-2-[[2-[4(5)-imidazolyl]ethyl]thio]imidazoles.
    Mor M; Bordi F; Silva C; Rivara S; Crivori P; Plazzi PV; Ballabeni V; Caretta A; Barocelli E; Impicciatore M; Carrupt PA; Testa B
    J Med Chem; 1997 Aug; 40(16):2571-8. PubMed ID: 9258364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series.
    Rivara M; Zuliani V; Cocconcelli G; Morini G; Comini M; Rivara S; Mor M; Bordi F; Barocelli E; Ballabeni V; Bertoni S; Plazzi PV
    Bioorg Med Chem; 2006 Mar; 14(5):1413-24. PubMed ID: 16263297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorinated non-imidazole histamine H3 receptor antagonists.
    Isensee K; Amon M; Garlapati A; Ligneau X; Camelin JC; Capet M; Schwartz JC; Stark H
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2172-5. PubMed ID: 19286376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligands of the histamine H3-receptor: new potent antagonists of the 2-thioimidazole type.
    Plazzi PV; Mor M; Bordi F; Silva C; Rivara S; Caretta A; Ballabeni V; Impicciatore M; Vitali T
    Farmaco; 1997 May; 52(5):295-302. PubMed ID: 9274000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.
    Witte DG; Yao BB; Miller TR; Carr TL; Cassar S; Sharma R; Faghih R; Surber BW; Esbenshade TA; Hancock AA; Krueger KM
    Br J Pharmacol; 2006 Jul; 148(5):657-70. PubMed ID: 16715122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.